What conditions does Abilify (aripiprazole) treat?

What Abilify (Aripiprazole) Treats

Abilify is FDA-approved to treat schizophrenia, acute manic and mixed episodes of bipolar I disorder, major depressive disorder (as adjunctive therapy), irritability associated with autistic disorder, and Tourette's disorder. 1

FDA-Approved Indications

The official FDA labeling establishes five primary treatment indications:

1. Schizophrenia

• Approved for adults and adolescents (13-17 years)
• Target dose: 10-15 mg/day for adults; 10 mg/day for adolescents
• Effective dose range: 10-30 mg/day, though higher doses show no additional benefit 1

2. Bipolar I Disorder - Acute Manic and Mixed Episodes

• Used as monotherapy or adjunctive therapy with lithium or valproate
• Starting dose: 15 mg/day (monotherapy) or 10-15 mg/day (adjunctive)
• May increase to 30 mg/day based on clinical response 1

3. Major Depressive Disorder (MDD)

• Only as adjunctive treatment with antidepressant medications
• Not approved as monotherapy for depression 1

4. Irritability Associated with Autistic Disorder

• Approved for children 6 years and older 1

5. Tourette's Disorder

• Approved for children 6 years and older 1

Additional Clinical Uses Supported by Guidelines

Augmentation Strategy in Schizophrenia

Recent international guidelines (2025) identify aripiprazole as a specific augmentation option for managing antipsychotic-related side effects, particularly hyperprolactinemia. When patients develop symptomatic or asymptomatic hyperprolactinemia on other antipsychotics, low-dose aripiprazole can be added as adjunctive therapy due to its dopamine D2 partial agonist properties 2.

Maintenance Treatment

For bipolar I disorder, aripiprazole is recommended as:

• First-line maintenance monotherapy following DSM-IV mixed episodes 3
• Effective in preventing recurrence of manic episodes (though less evidence for preventing depressive episodes) 4

Important Safety Warnings

The FDA mandates two black box warnings:

1. Increased mortality risk in elderly patients with dementia-related psychosis (NOT an approved indication) 1

2. Suicidal thoughts and behaviors in children, adolescents, and young adults when used for depression—requires close monitoring especially during initial treatment months 1

Critical Caveats

• Not approved for dementia-related psychosis despite being an antipsychotic 1
• When used for depression, must be combined with antidepressants—never use as monotherapy 1
• Age restrictions apply: not studied in children under 13 for schizophrenia, under 10 for bipolar disorder, or under 6 for autism/Tourette's 1
• Can cause compulsive behaviors including pathological gambling—screen patients for history of impulse control issues before prescribing 5

Mechanism Supporting These Indications

Aripiprazole functions as a dopamine D2 partial agonist (unique among antipsychotics) and serotonin 5-HT1A partial agonist, with 5-HT2A antagonism 6. This profile provides antipsychotic efficacy while potentially reducing metabolic side effects, prolactin elevation, and extrapyramidal symptoms compared to full D2 antagonists 7, 8.